规格

价格

库存

数量

5 mg

¥ 8,190

5日内发货

25 mg

待询

5日内发货

50 mg

待询

5日内发货

100 mg

待询

5日内发货

生物活性

产品描述	Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).
靶点活性	CDK4-CyclinD1:3.96 nM (ki), CDK9-CyclinT1:1.68 nM (ki), CDK6-CyclinD1:2.92 nM (ki), CDK1-CyclinB:5.4 nM (ki), CDK9-CyclinT2:0.626 nM (ki), CDK1-CyclinA:9.1 nM (ki)
体外活性	In both ABC and GCB subtypes, Voruciclib hydrochloride (0.5-5 μM; 6 hours) shows targeted downregulation of MCL-1 . Ki values for each target such as CDK9/cyc T2, CDK9/cyc T1, CDK6/cyc D1, CDK4/cyc D1, CDK1/cyc B, and CDK1/cyc A for Voruciclib hydrochloride are 0.626 nM, 1.68 nM, 2.92 nM, 3.96 nM, 5.4 nM, 9.1 nM, respectively.
体内活性	Combination of Venetoclax (10 mpk, 1 mpk, 50 mpk, 25 mpk in U2932, RIVA, SU-DHL-4 and NU-DHL-1, respectively) and Voruciclib hydrochloride (200 mpk; Oral gavage) leads to enhance tumor growth inhibition compared to either drug alone in U2932, RIVA, SU-DHL-4 (six days per week for 4 weeks), and NU-DHL-1 models (five days per week for 3 weeks) of DLBCL.

化学信息

分子量	506.3
分子式	C₂₂H₂₀Cl₂F₃NO₅
CAS No.	1000023-05-1
Smiles	Cl.CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F
密度	no data available

储存&溶解度

存储

溶解度信息

DMSO: 250 mg/mL (493.78 mM), Sonication is recommended.

体内实验配方

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.52 mM), Sonication is recommended.

请按顺序添加溶剂，在添加下一种溶剂之前，尽可能使溶液澄清。如有必要，可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考，体内配方并不是绝对的，请根据不同情况进行调整。

溶液配制表

DMSO

该溶液配制表仅适用于固体产品。对于液体产品，请根据标明的浓度或密度计算稀释方案。

Voruciclib hydrochloride